RT Journal
A1 Kuehn BM
T1 TO battle deadly infections, clinicians draw on both new and old tools
JF JAMA
JO JAMA
YR 2012
FD October 10
VO 308
IS 14
SP 1417
OP 1418
DO 10.1001/jama.2012.12574
UL http://dx.doi.org/10.1001/jama.2012.12574
AB 
In some areas, such as New York, physicians now regularly battle such carbapenem-resistant Enterobacteriaceae (CRE) infections. Because effective treatment options are limited, serious infections are associated with death rates as high as 40%. Fortunately, most US hospitals have yet to see CRE infections, with only about 6% of hospitals across the country having encountered a case, according to CDC estimates. This means there's still an opportunity to prevent the spread of this type of infection before it becomes endemic at all facilities, as methicillin-resistant Staphylococcus aureus (MRSA) has, said Abbigail Tumpey, MPH, associate director for communications science in the CDC's Division of Healthcare Quality Promotion.